Lazarus, ?; Anstee, Quentin M.; Hagstrom, Hannes et al.
Defining comprehensive models of care for NAFLDNATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY. Bd. 18. H. 10. 2021 S. 717-729
Rosigkeit, Sebastian; Kruchem, Marie; Thies, Dorothe et al.
Definitive evidence for Club cells as progenitors for mutant Kras/Trp53-deficient lung cancerINTERNATIONAL JOURNAL OF CANCER. Bd. 149. H. 9. 2021 S. 1670-1682
Labenz, Christian; Toenges, Gerrit; Galle, Peter et al.
Derivation and validation of the NAFLD cirrhosis score (NCS) to distinguish bridging fibrosis from cirrhosis and to predict liver-related outcomesJOURNAL OF HEPATOLOGY. Bd. 75. 2021 S. S556-S557
Erhardtsen, Elisabeth; Rasmussen, Daniel G. K.; Frederiksen, Peder et al.
Determining a healthy reference range and factors potentially influencing PRO-C3 - A biomarker of liver fibrosisJHEP REPORTS. Bd. 3. H. 4. 2021
Docherty, Matt; Regnier, Stephane A.; Capkun, Gorana et al.
Development of a novel machine learning model to predict presence of nonalcoholic steatohepatitisJOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION. Bd. 28. H. 6. 2021 S. 1235-1241
Schmitt, Volker H.; Hobohm, Lukas; Sivanathan, Visvakanth et al.
Diabetes mellitus and its impact on mortality rate and outcome in pulmonary embolismJOURNAL OF DIABETES INVESTIGATION. Bd. 13. H. 4. 2021 S. 725-737
Mozes, Ferenc Emil; Lee, Jenny A.; Selvaraj, Emmanuel Anandraj et al.
Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysisGUT. Bd. 71. H. 5. 2021 S. 1006-1019
Schattenberg, Jorn M.; Anstee, Quentin M.; Caussy, Cyrielle et al.
Differences between current clinical guidelines for screening, diagnosis and management of nonalcoholic fatty liver disease and real-world practice: a targeted literature reviewEXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY. Bd. 15. H. 11. 2021 S. 1253-1266
Franck, Caspar; Zimmermann, Nadja; Goni, Elisabetta et al.
Different Prevalence of Alarm, Dyspeptic and Reflux Symptoms in Patients with Cardia and Non-cardia Gastric CancerJOURNAL OF GASTROINTESTINAL AND LIVER DISEASES. Bd. 30. H. 4. 2021 S. 431-437
Schattenberg, Jorn M.; Lazarus, Jeffrey V.; Newsome, Philip N. et al.
Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis in five European countries in 2018: A cost-of-illness analysisLIVER INTERNATIONAL. Bd. 41. H. 6. 2021 S. 1227-1242
Albert, Joerg; Weinmann, Arndt; Rathmayer, Markus et al.
DRG Update Autumn 2021ZEITSCHRIFT FUR GASTROENTEROLOGIE. Bd. 59. H. 12. 2021 S. 1426-1438
Fontana, Elisa; Meyers, Jeff; Sobrero, Alberto et al.
Early-Onset Colorectal Adenocarcinoma in the IDEA Database: Treatment Adherence, Toxicities, and Outcomes With 3 and 6 Months of Adjuvant Fluoropyrimidine and OxaliplatinJOURNAL OF CLINICAL ONCOLOGY. Bd. 39. H. 36. 2021 S. 4009-+
Fontana, Elisa; Meyers, Jeffrey P.; Sobrero, Alberto F. et al.
Early-onset stage II/III colorectal adenocarcinoma in the IDEA database: Treatment adherence, toxicities, and outcomes from adjuvant fluoropyrimidine and oxaliplatin.JOURNAL OF CLINICAL ONCOLOGY. Bd. 39. H. 15. 2021
Armandi, Angelo; Schattenberg, Joern M.
Editorial: the polygenic risk of cirrhosis developmentALIMENTARY PHARMACOLOGY & THERAPEUTICS. Bd. 53. H. 7. 2021 S. 849-850
Kudo, Masatoshi; Galle, Peter R.; Brandi, Giovanni et al.
Effect of ramucirumab on ALBI grade in patients with advanced HCC: Results from REACH and REACH-2JHEP REPORTS. Bd. 3. H. 2. 2021
Dietz, Julia; Spengler, Ulrich; Mullhaupt, Beat et al.
Efficacy of Retreatment After Failed Direct-acting Antiviral Therapy in Patients With HCV Genotype 1-3 InfectionsCLINICAL GASTROENTEROLOGY AND HEPATOLOGY. Bd. 19. H. 1. 2021 S. 195-+
Michel, Maurice; Hess, Cornelius; Kaps, Leonard et al.
Elevated serum levels of methylglyoxal are associated with impaired liver function in patients with liver cirrhosisSCIENTIFIC REPORTS. Bd. 11. H. 1. 2021
Smyth, Elizabeth Catherine; Peeters, Ellen; Knoedler, Maren Kristina et al.
EORTC 1707 VESTIGE: Adjuvant immunotherapy in patients with resected gastric cancer following preoperative chemotherapy with high risk for recurrence (ypN+ and/ or R1)-An open-label randomized controlled phase II study.JOURNAL OF CLINICAL ONCOLOGY. Bd. 39. H. 15. 2021
Czauderna, Carolin; Poplawski, Alicia; O'Rourke, Colm J. et al.
Epigenetic modifications precede molecular alterations and drive human hepatocarcinogenesisJCI INSIGHT. Bd. 6. H. 17. 2021
Haeuser, Friederike; Sprinzl, Martin F.; Dreis, Kim J. et al.
Evaluation of a laboratory-based high-throughput SARS-CoV-2 antigen assay for non-COVID-19 patient screening at hospital admissionMEDICAL MICROBIOLOGY AND IMMUNOLOGY. Bd. 210. H. 2-3. 2021 S. 165-171
Gerges, Christian; Neumann, ?; Ishaq, Sauid et al.
Evaluation of a novel colonoscope offering flexibility adjuster - a retrospective observational studyTHERAPEUTIC ADVANCES IN GASTROENTEROLOGY. Bd. 14. 2021
Neumann, Helmut; Kreft, Andreas; Sivanathan, Visvakanth et al.
Evaluation of novel LCI CAD EYE system for real time detection of colon polypsPLOS ONE. Bd. 16. H. 8. 2021
Deutschbein, Timo; Jaursch-Hancke, Cornelia; Knappe, Ulrich J. et al.
First German Guideline on Diagnostics and Therapy of Clinically Non-Functioning Pituitary TumorsEXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES. Bd. 129. H. 3. 2021 S. 250-264
Moehler, Markus H.; Shitara, Kohei; Garrido, Marcelo et al.
First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) versus chemo in advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): Expanded efficacy and safety data from CheckMate 649.JOURNAL OF CLINICAL ONCOLOGY. Bd. 39. H. 15. 2021
Moehler, M.; Shitara, K.; Garrido, M. et al.
First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): expanded efficacy and safety data from CheckMate 649ONCOLOGY RESEARCH AND TREATMENT. Bd. 44. 2021 S. 79-80
Janjigian, Yelena Y.; Shitara, Kohei; Moehler, Markus et al.
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trialLANCET. Bd. 398. H. 10294. 2021 S. 27-40
Moehler, M.; Valle, J. W.; Hollebecque, A. et al.
Foenix-CCA2 quality of life data for Futibatinib-treated intrahepatic cholangiocarcinoma (ICCA) patients with FGFR2 fusions/rearrangementsONCOLOGY RESEARCH AND TREATMENT. Bd. 44. 2021 S. 223-224
Heinemann, Volker; von Weikersthal, Ludwig Fischer; Decker, Thomas et al.
FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trialBRITISH JOURNAL OF CANCER. Bd. 124. H. 3. 2021 S. 587-594
Vollmar, Johanna; Kim, Yong Ook; Marquardt, Jens Uwe et al.
Functional inhibition of Oct leads to HNF4 alpha upregulationEXPERIMENTAL AND THERAPEUTIC MEDICINE. Bd. 21. H. 4. 2021
McNamara, Mairead Geraldine; Bridgewater, John A.; Goyal, Lipika et al.
Gender representation in authorship in later-phase systemic clinical trials in biliary tract cancer (BTC).JOURNAL OF CLINICAL ONCOLOGY. Bd. 39. H. 3. 2021
Sen, Partho; Govaere, Olivier; Sinioja, Tim et al.
Genome-scale metabolic modeling of human hepatocytes reveals dysregulation of glycosphingolipid pathways in progressive non-alcoholic fatty liver diseaseJOURNAL OF HEPATOLOGY. Bd. 75. 2021 S. S256-S256
Anstee, Quentin M.; Darlay, Rebecca; Cockell, Simon et al.
Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort (vol 12, pg 505, 2020)JOURNAL OF HEPATOLOGY. Bd. 74. H. 5. 2021 S. 1274-1275
Engelmann, Cornelius; Herber, Adam; Franke, Annegret et al.
Granulocyte-colony stimulating factor (G-CSF) to treat acute-on- chronic liver failure: A multicenter randomized trial (GRAFT study)JOURNAL OF HEPATOLOGY. Bd. 75. H. 6. 2021 S. 1346-1354
Engelmann, Cornelius; Herber, Adam; Ildh, Tony et al.
GRANULOCYTE-COLONY STIMULATING FACTOR (G-CSF) TO TREAT ACUTE-ON-CHRONIC LIVER FAILURE; RESULTS OF THE FIRST MULTICENTER RANDOMIZED TRIAL (GRAFT STUDY)GUT. Bd. 70. 2021 S. A6-A6
Krieger, Christine C.; Kahaly, George J.; Azam, Asma et al.
Graves' Autoantibodies Exhibit Different Stimulating Activities in Cultures of Thyrocytes and Orbital Fibroblasts Not Reflected by Clinical AssaysTHYROID. 2021
Moehler, M.; Elimova, E.; Blum, ? et al.
Health-related quality of life (HRQOL) in patients (pts) with advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC) or esophageal adenocarcinoma (EAC): Interim results of nivolumab plus chemotherapy (N plus C) versus (C) from CheckMate 649ONCOLOGY RESEARCH AND TREATMENT. Bd. 44. 2021 S. 214-215
Wyrwicz, Lucjan; Elimova, Elena; Blum, Steven I. et al.
Health-related quality of life (HRQOL) in patients (pts) with advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC) or esophageal adenocarcinoma (EAC): Interim results of nivolumab plus chemotherapy (N plus C) versus (C) from CheckMate 649.JOURNAL OF CLINICAL ONCOLOGY. Bd. 39. H. 15. 2021
Elimova, Elena; Wyrwicz, Lucjan; Blum, Steven I. et al.
Health-related quality of life (HRQOL) in patients (pts) with advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC) or esophageal adenocarcinoma (EAC): Results of nivolumab plus chemotherapy (NIVO plus chemo) versus chemo from CheckMate 649JOURNAL OF CLINICAL ONCOLOGY. Bd. 39. H. 28. 2021
Michel, Maurice; Spinelli, Francesca; Grambihler, Annette et al.
Health-related quality of life in patients with autoimmune hepatitisQUALITY OF LIFE RESEARCH. Bd. 30. H. 10. 2021 S. 2853-2861
Graf, Christiana; Arncken, Jeannette; Lange, Christian M. et al.
Hepatic sarcoidosis: Clinical characteristics and outcomeJHEP REPORTS. Bd. 3. H. 6. 2021
Maehringer-Kunz, Aline; Meyer, Franziska I.; Hahn, Felix et al.
Hepatic vein tumor thrombosis in patients with hepatocellular carcinoma: Prevalence and clinical significanceUNITED EUROPEAN GASTROENTEROLOGY JOURNAL. Bd. 9. H. 5. 2021 S. 590-597
Czauderna, Carolin; Schmidtmann, Irene; Koch, Sandra et al.
High pretreatment static and dynamic alpha-fetoprotein values predict reduced overall survival in hepatocellular carcinomaUNITED EUROPEAN GASTROENTEROLOGY JOURNAL. Bd. 9. H. 3. 2021 S. 388-397
Koessler, Thibaud; Alsina, Maria; Arnold, Dirk et al.
Highlights from ASCO-GI 2021 from EORTC Gastrointestinal tract cancer groupBRITISH JOURNAL OF CANCER. Bd. 125. H. 7. 2021 S. 911-919
Stoehr, Fabian; Mueller, Lukas; Brady, Adrian et al.
How COVID-19 kick-started online learning in medical education-The DigiMed studyPLOS ONE. Bd. 16. H. 9. 2021
Ducreux, Michel; Zhu, Andrew X.; Cheng, Ann-Lii et al.
IMbrave150: Exploratory analysis to examine the association between treatment response and overall survival (OS) in patients (pts) with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab (atezo) plus bevacizumab (bev) versus sorafenib (sor).JOURNAL OF CLINICAL ONCOLOGY. Bd. 39. H. 15. 2021
Zhu, Andrew X.; Finn, Richard; Ducreux, Michel et al.
IMbrave150: EXPLORATORY EFFICACY AND SAFETY OF ATEZOLIZUMAB (ATEZO) plus BEVACIZUMAB (BEV) VS SORAFENIB (SOR) IN PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC) WITH NON-VIRAL ETIOLOGY IN A GLOBAL PHASE III STUDYHEPATOLOGY. Bd. 74. 2021 S. 646A-647A
Breder, Valeriy Vladimirovich; Vogel, Arndt; Merle, Philippe et al.
IMbrave150: Exploratory efficacy and safety results of hepatocellular carcinoma (HCC) patients (pts) with main trunk and/or contralateral portal vein invasion (Vp4) treated with atezolizumab (atezo) plus bevacizumab (bev) versus sorafenib (sor) in a global Ph III study.JOURNAL OF CLINICAL ONCOLOGY. Bd. 39. H. 15. 2021
Finn, Richard S.; Qin, Shukui; Ikeda, Masafumi et al.
IMbrave150: updated efficacy and safety by risk status in patients (pts) receiving atezolizumab (atezo) plus bevacizumab (bev) vs sorafenib (sor) as first-line treatment for unresectable hepatocellular carcinoma (HCC)SWISS MEDICAL WEEKLY. Bd. 151. 2021 S. 25-26
Finn, Richard S.; Qin, Shukui; Ikeda, Masafumi et al.
IMbrave150: Updated efficacy and safety by risk status in patients (pts) receiving atezolizumab (atezo) plus bevacizumab (bev) vs sorafenib (sor) as first-line treatment for unresectable hepatocellular carcinoma (HCC).CANCER RESEARCH. Bd. 81. H. 13. 2021
Finn, Richard S.; Qin Shukui, ?; Ikeda, Masafumi et al.
IMbrave150: Updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) plus bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC).JOURNAL OF CLINICAL ONCOLOGY. Bd. 39. H. 3. 2021